Cytotoxic effects of mistletoe (Viscum album L.) in head and neck squamous cell carcinoma cell lines

Klingbeil,M. Fátima G.; Xavier,Flávia  C.A.; Sardinha,Luiz  R.; Severino,Patricia; Mathor,Monica  B.; Rodrigues,Rodrigo   V.; Pinto ,Décio   S.

doi:10.3892/or.2013.2732

Cytotoxic effects of mistletoe (Viscum album L.) in head and neck squamous cell carcinoma cell lines

Authors:
- M. Fátima G. Klingbeil
- Flávia C.A. Xavier
- Luiz R. Sardinha
- Patricia Severino
- Monica B. Mathor
- Rodrigo V. Rodrigues
- Décio S. Pinto
View Affiliations

Affiliations: Department of Oral Pathology, School of Dentistry, University of São Paulo, 05508-000 São Paulo, Brazil, Federal University of Bahia, School of Dentistry Salvador, Canela, 40110-150 Bahia, Brazil, Centro de Pesquisa Experimental do Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE), 0565-000 São Paulo, Brazil , Centro de Pesquisa Experimental do Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE), 0565-000 São Paulo, Brazil, Radiation Technology Center (CTR), Nuclear and Energetic Research Institute (IPEN-CNEN/SP), 05508-000 São Paulo, Brazil, Department of Genetics and Evolutionary Biology, Institute of Biosciences, University of São Paulo, 05508-090 São Paulo, Brazil
Published online on: September 10, 2013 https://doi.org/10.3892/or.2013.2732
Pages: 2316-2322

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Head and neck squamous cell carcinoma is a complex disease with several etiologic factors and different molecular changes that may trigger certain events; it is also globally one of the most common malignancies in this topography. Extracts from Viscum album L. (VA) (mistletoe) have been used as adjuvant therapies with promising results in several types of cancer, mainly in European countries. In vitro studies have demonstrated that various types of VA may have cytotoxicity in carcinoma cells, activating the apoptotic cascade or leading cells to necrosis. This study aimed to verify the effects of three types of VA extracts (Iscador Qu Spezial, Iscador P and Iscador M) in squamous cell carcinoma of the tongue cell lines SCC9 and SCC25, not previously studied. A concentration of 0.3 mg/ml (IC50) of the drugs induced apoptosis, affecting gene expression and protein levels of AKT, PTEN and CYCLIN D1. It was concluded that VA extracts have a cytotoxic effect on SCC9 and SCC25 cell lines, but while SCC9 cell line was more resistant to the action of the drugs, Iscador Qu Spezial and Iscador M have higher cytotoxic potential in both cell lines compared to Iscador P.

View Figures

View References

1	Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al: Cancer statistics, 2004. CA Cancer J Clin. 54:8–29. 2004. View Article : Google Scholar
2	Warnakulasuriya S: Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 45:309–316. 2009. View Article : Google Scholar
3	Sklenicka S, Gardiner S, Dierks EJ, Potter BE and Bell RB: Survival analysis and risk factors for recurrence in oral squamous cell carcinoma: does surgical salvage affect outcome? J Oral Maxillofac Surg. 68:1270–1275. 2010. View Article : Google Scholar : PubMed/NCBI
4	Tsantoulis PK, Kastrinakis NG, Tourvas AD, Laskaris G and Gorgoulis VG: Advances in the biology of oral cancer. Oral Oncol. 43:523–534. 2007. View Article : Google Scholar : PubMed/NCBI
5	Miller CS and Johnstone BM: Human papillomavirus as a risk factor for oral squamous cell carcinoma: a meta-analysis, 1982–1997. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 91:622–635. 2001.PubMed/NCBI
6	Scully C and Bagan J: Oral squamous cell carcinoma overview. Oral Oncol. 45:301–308. 2009. View Article : Google Scholar : PubMed/NCBI
7	Gold KA, Lee HY and Kim ES: Targeted therapies in squamous cell carcinoma of the head and neck. Cancer. 115:922–935. 2009. View Article : Google Scholar : PubMed/NCBI
8	Corvò R: Evidence-based radiation oncology in head and neck squamous cell carcinoma. Radiother Oncol. 85:156–170. 2007.PubMed/NCBI
9	Bernier J: Current state-of-the-art for concurrent chemoradiation. Semin Radiat Oncol. 19:3–10. 2009. View Article : Google Scholar : PubMed/NCBI
10	Bellacosa A, Kumar CC, Di Cristofano A and Testa JR: Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res. 94:29–86. 2005. View Article : Google Scholar : PubMed/NCBI
11	Cicenas J: The potential role of Akt phosphorylation in human cancers. Int J Biol Markers. 23:1–9. 2008.PubMed/NCBI
12	Molinolo AA, Amornphimoltham P, Squarize CH, Castilho RM, Patel V and Gutkind JS: Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol. 45:324–334. 2009. View Article : Google Scholar : PubMed/NCBI
13	Okumura K, Mendoza M, Bachoo RM, DePinho RA, Cavenee WK and Furnari FB: PCAF modulates PTEN activity. J Biol Chem. 281:26562–26568. 2006. View Article : Google Scholar : PubMed/NCBI
14	Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, et al: Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 15:356–362. 1997. View Article : Google Scholar : PubMed/NCBI
15	Kurasawa Y, Shiiba M, Nakamura M, Fushimi K, Ishigami T, Bukawa H, et al: PTEN expression and methylation status in oral squamous cell carcinoma. Oncol Rep. 19:1429–1434. 2008.PubMed/NCBI
16	Lundberg AS and Weinberg RA: Control of the cell cycle and apoptosis. Eur J Cancer. 35:531–539. 1999. View Article : Google Scholar : PubMed/NCBI
17	el-Naggar AK, Steck K and Batsakis JG: Heterogeneity of the proliferative fraction and cyclin D1/CCND1 gene amplification in head and neck squamous cell carcinoma. Cytometry. 21:47–51. 1995. View Article : Google Scholar : PubMed/NCBI
18	Zuzak TJ, Rist L, Eggenschwiler J, Grotzer MA and Viviani A: Paediatric medulloblastoma cells are susceptible to Viscum album (mistletoe) preparations. Anticancer Res. 26:3485–3492. 2006.PubMed/NCBI
19	Harmsma M, Grommé M, Ummelen M, Dignef W, Tusenius KJ and Ramaekers FC: Differential effects of Viscum album extract Iscador Qu on cell cycle progression and apoptosis in cancer cells. Int J Oncol. 25:1521–1529. 2004.
20	Goedings P: Über die bildung von Viscum album L. Element der Naturwissenschaft. 67:1–23. 1997.(In German).
21	Molassiotis A, Scott JA, Kearney N, Pud D, Magri MS, et al: Complementary and alternative medicine use in breast cancer patients in Europe. Support Care Cancer. 14:260–267. 2006. View Article : Google Scholar : PubMed/NCBI
22	Eggenschwiler J, Patrignani A, Wagner U, Rehrauer H, Schlapbach R, Rist L, et al: Gene expression profiles of different breast cancer cells compared with their responsiveness to fermented mistletoe (Viscum album L.) extracts Iscador from oak (Quercus), pine (Pinus), white fir (Abies) and apple tree (Malus) in vitro. Arzneimittelforschung. 56:483–496. 2006.PubMed/NCBI
23	Urech K, Buessing A, Thalmann G, Schaefermeyer H and Heusser P: Antiproliferative effects of mistletoe (Viscum album L.) extract in urinary bladder carcinoma cell lines. Anticancer Res. 26:3049–3055. 2006.
24	Matthes H, Friedel WE, Bock PR and Zänker KS: Molecular mistletoe therapy: friend or foe in established anti-tumor protocols? A multicenter, controlled, retrospective pharmaco-epidemiological study in pancreas cancer. Curr Mol Med. 10:430–439. 2010. View Article : Google Scholar
25	Maier G and Fiebig HH: Absence of tumor growth stimulation in a panel of 16 human tumor cell lines by mistletoe extracts in vitro. Anticancer Drugs. 13:373–379. 2002. View Article : Google Scholar : PubMed/NCBI
26	Pedrero JM, Carracedo DG, Pinto CM, Zapatero AH, Rodrigo JP, Nieto CS, et al: Frequent genetic and biochemical alterations of the PI3K/Akt/PTEN pathway in head and neck squamous cell carcinoma. Int J Cancer. 114:242–248. 2005. View Article : Google Scholar : PubMed/NCBI
27	Cheng JQ, Ruggeri B, Klein WM, Sonoda G, Altomare DA, Watson DK and Testa JR: Amplification of Akt2 in human pancreatic cells and inhibition of Akt2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci USA. 93:3636–3641. 1996. View Article : Google Scholar : PubMed/NCBI
28	Brazil DP, Yang ZZ and Hemmings BA: Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci. 29:233–242. 2004. View Article : Google Scholar : PubMed/NCBI
29	Diehl JA, Zindy F and Sherr CJ: Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev. 11:957–972. 1997. View Article : Google Scholar : PubMed/NCBI
30	Sauter ER, Nesbit M, Litwin S, Klein-Szanto AJ, Cheffetz S and Herlyn M: Antisense cyclin D1 induces apoptosis and tumor shrinkage in human squamous carcinoma. Cancer Res. 59:4876–4881. 1999.PubMed/NCBI
31	Baldin V, Lukas J, Marcote MJ, Pagano M and Draetta G: Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev. 7:812–821. 1993. View Article : Google Scholar : PubMed/NCBI
32	Altomare DA and Testa JR: Perturbations of the AKT signaling pathway in human cancer. Oncogene. 24:7455–7464. 2005. View Article : Google Scholar : PubMed/NCBI
33	Vivanco I and Sawyers CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2:489–501. 2002. View Article : Google Scholar : PubMed/NCBI
34	Andjelkovic M, Alessi DR, Meier R, Fernandez A, Lamb NJ, Frech M, et al: Role of translocation in the activation and function of protein kinase B. J Biol Chem. 272:31515–31524. 1997. View Article : Google Scholar : PubMed/NCBI
35	Nicholson KM and Anderson NG: The protein kinase B/Akt signaling pathway in human malignancy. Cell Signal. 14:381–395. 2002. View Article : Google Scholar : PubMed/NCBI
36	Shen WH, Balajee AS, Wang J, Wu H, Eng C, Pandolfi PP, et al: Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell. 128:157–170. 2007. View Article : Google Scholar : PubMed/NCBI
37	Trotman LC, Wang X, Alimonti A, Chen Z, Teruya-Feldstein J, Yang H, et al: Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell. 128:141–156. 2007. View Article : Google Scholar : PubMed/NCBI
38	Perren A, Komminoth P, Saremaslani P, Matter C, Feurer S, Lees JA, et al: Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am J Pathol. 157:1097–1103. 2000. View Article : Google Scholar
39	Gimm O, Perren A, Weng LP, Marsh DJ, Yeh JJ, Ziebold U, et al: Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. Am J Pathol. 156:1693–1700. 2000. View Article : Google Scholar : PubMed/NCBI
40	Cully M, You H, Levine AJ and Mak TW: Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer. 6:184–192. 2006. View Article : Google Scholar : PubMed/NCBI